Research Summary

My work focuses on the prevention and treatment of HIV infection.

I have been involved in studies of HIV prevention (specifically, truvada for PrEP) for over 12 years. I was the statistician for the iPrEx trial -- the first trial to report the efficacy of oral PrEP and worked on the drugs approval by the FDA. My current work involves studies of the global scale-up of PrEP, innovative designs/statistical analyses of new PrEP agents, and pharmacologic markers of PrEP exposure.

I also collaborate on studies on the outcomes of HIV treatment in resource limited settings. In these settings many patients are absent from clinics. This data requires handling several statistical issues including clustering, competing risk/multiple outcomes, time-dependent covariates and informative censoring. My colleagues and I have pioneered sampling based approaches to losses to follow-up which have given rigorous information about treatment outcomes.

I also collaborate for groups in neurology, pediatrics, LGBT health and nephrology and teach in my department's MCR and Ph.D. program.

Research Funding

  • September 24, 2018 - August 31, 2022 - Statistical methods for clinical trials of novel PrEP agents , Principal Investigator . Sponsor: NIH/NIAIDS, Sponsor Award ID: R01AI143357
  • January 10, 2016 - December 31, 2017 - Comparison of Pharmacologic Markers of Exposure to HIV Pre-Exposure Prophylaxis , Principal Investigator . Sponsor: NIH, Sponsor Award ID: R03AI122908
  • June 19, 2015 - May 31, 2017 - Chemoprophylaxis for HIV Prevention: Analysis of Bone and Metabolic Effects , Principal Investigator . Sponsor: NIH, Sponsor Award ID: R03AI120819
  • April 1, 2001 - March 31, 2006 - FAILURE TIME METHODS FOR FAMILY DISEASE STUDIES , Principal Investigator . Sponsor: NIH, Sponsor Award ID: R01HL065411

Education

University of California, Berkeley, CA, BA, 1988, Statistics
University of Washington, Seattle, WA, PhD, 1993, Biostatistics
Harvard University, Boston, MA, Fellowship, 1995, Biostatistics

Honors & Awards

  • 1988
    W.W. Stout Fellowship, Graduate School, University of Washington
  • 1988 - 1990
    Graduate Fellowship Award, Graduate School, University of Washington
  • 1990 - 1993
    National Research Service Award, National Heart, Lung and Blood Institute
  • 1993
    School of Public Health Outstanding Student Citation for Biostatistics, Univ. of Washington
  • 2007
    TICR Award for Excellence in Teaching

Selected Publications

  1. Beavers C, Pau AK, Glidden D, Hyle E, Kuriakose S, Martin SS, McComsey G, Thompson M, Virani S, Baker JV Statin Therapy as Primary Prevention for Persons With HIV: A Synopsis of Recommendations From the U.S. Department of Health and Human Services Antiretroviral Treatment Guidelines Panel.  View on PubMed
  2. Nadig N, Bhimraj A, Cawcutt K, Chiotos K, Dzierba AL, Kim AY, Martin GS, Pearson JC, Shumaker AH, Baden LR, Bedimo R, Cheng VC, Chew KW, Daar ES, Glidden DV, Hardy EJ, Johnson S, Li JZ, MacBrayne C, Nakamura MM, Riley L, Shafer RW, Shoham S, Tebas P, Tien PC, Loveless J, Falck-Ytter Y, Morgan RL, Gandhi RT 2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Vilobelimab.  View on PubMed
  3. Buccheri R, Spinelli MA, Heise MJ, Glidden DV, Sassaman K, Martinson T, Schmidt HR, D'Angelo AB, Duncan DT, Horvath KJ, Hirshfield S, Williams RS, Johnson MO, Grov C, Carrico A, Gandhi M Feasibility of Point-of-Care Urine Self-Testing to Measure Tenofovir Adherence and Predict Viral Suppression.  View on PubMed
  4. Moses JS, Pau AK, Kuriakose S, Grandits G, Reilly C, Sherman BT, Chang W, Dai L, Khan MA, Highbarger H, Mannah M, McCullough J, Chorley C, Morlu I, Dorbor J, Bongolee OT, Slewion R, Akpa E, Wilson B, Poole AL, Kopka SL, Miller T, Nuta CJ, Lindan C, Glidden D, Martin JN, Johnson KL, Dewar RL, Wachekwa I, Migueles SA HIV-1 suppression and rare dolutegravir resistance in antiretroviral-experienced people with HIV in Liberia.  View on PubMed
  5. Gebreegziabher EA, Ouattara M, Bountogo M, Coulibaly B, Boudo V, Ouedraogo T, Lebas E, Hu H, O'Brien KS, Hsiang MS, Glidden DV, Arnold BF, Lietman TM, Sié A, Oldenburg CE The role of Seasonal Malaria Chemoprevention in the effect of Azithromycin on Child Mortality: A Secondary Analysis of the CHAT Cluster Randomized Clinical Trial.  View on PubMed
  6. Moore M, Glidden D, Anderson P, Hendrix C, Dimitrov D Dosing forgiveness of oral PrEP for cisgender women remains uncertain.  View on PubMed
  7. Chitre S, Barrie MB, Kanu JS, Conteh TS, Bayoh M, Kamara MN, Bangura HF, Lascher JS, Frankfurter R, Goldberg SA, Glidden DV, Kelly JD, Lakoh S, Richardson ET Post-Omicron SARS-CoV-2 antibody prevalence in Sierra Leone: A cross-sectional, nationally representative, follow-up serosurvey.  View on PubMed
  8. Peluso MJ, Sandel DA, Deitchman AN, Kim SJ, Dalhuisen T, Tummala HP, Tibúrcio R, Zemelko L, Borgo GM, Singh SS, Schwartz K, Deswal M, Williams MC, Hoh R, Shimoda M, Narpala S, Serebryannyy L, Khalili M, Vendrame E, SenGupta D, Whitmore LS, Tisoncik-Go J, Gale M, Koup RA, Mullins JI, Felber BK, Pavlakis GN, Reeves JD, Petropoulos CJ, Glidden DV, Spitzer MH, Gama L, Caskey M, Nussenzweig MC, Chew KW, Henrich TJ, Yukl SA, Cohn LB, Deeks SG, Rutishauser RL. Combination immunotherapy induces post-intervention control of HIV. Res Sq. 2025 Mar 19.  View on PubMed
  9. Guan A, Wesson P, Glidden DV, Hamad R, Tan JY, Gomez SL. LGB (lesbian, gay, and bisexual) state policy protections and substance use disparities. Health Aff Sch. 2025 Mar; 3(3):qxaf029.  View on PubMed
  10. Spinelli MA, Heise MJ, Gistand N, Cox C, Grochowski J, Oskarsson J, Glidden DV, Gandhi M. HIV Viral Suppression With Use of Long-Acting Antiretroviral Therapy in People With and Without Initial Viremia. JAMA. 2025 Mar 06.  View on PubMed
  11. Crook S, Rosenbluth G, Glidden DV, Fernandez A, Lee CM, Avina L, Magana L, Washington K, Bardach NS. Variations in digital health literacy for pediatric caregivers of hospitalized children: implications for digital health equity. J Am Med Inform Assoc. 2025 Mar 01; 32(3):572-578.  View on PubMed
  12. Rodriguez Almaraz E, Guerra GA, Al-Adli NN, Young JS, Dada A, Quintana D, Taylor JW, Oberheim Bush NA, Clarke JL, Butowski NA, de Groot J, Pekmezci M, Perry A, Bollen AW, Scheffler AW, Glidden DV, Phillips JJ, Costello JF, Chang EF, Hervey-Jumper S, Berger MS, Francis SS, Chang SM, Solomon DA. Longitudinal profiling of IDH-mutant astrocytomas reveals acquired RAS-MAPK pathway mutations associated with inferior survival. Neurooncol Adv. 2025 Jan-Dec; 7(1):vdaf024.  View on PubMed
  13. Sankaran M, Glidden DV, Kohn RP, Nguyen TQ, Bacon O, Buchbinder SP, Gandhi M, Havlir DV, Liebi C, Luetkemeyer AF, Nguyen JQ, Roman J, Scott H, Torres TS, Cohen SE. Doxycycline Postexposure Prophylaxis and Sexually Transmitted Infection Trends. JAMA Intern Med. 2025 Jan 06.  View on PubMed
  14. Bhimraj A, Falck-Ytter Y, Kim AY, Li JZ, Baden LR, Johnson S, Shafer RW, Shoham S, Tebas P, Bedimo R, Cheng VC, Chew KW, Chiotos K, Daar ES, Dzierba AL, Glidden DV, Hardy EJ, Martin GS, MacBrayne C, Nadig N, Nakamura MM, Shumaker AH, Tien P, Loveless J, Morgan RL, Gandhi RT. 2024 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Management of COVID-19: Anti-SARS-CoV-2 Neutralizing Antibody Pemivibart for Pre-exposure Prophylaxis. Clin Infect Dis. 2024 Oct 29.  View on PubMed
  15. Schaefer R, Donaldson L, Leus M, Osakwe CE, Chimukangara B, Dalal S, Duerr A, Gao F, Glidden DV, Grinsztejn B, Justman J, Kumwenda G, Laeyendecker O, Lee HY, Maldarelli F, Mayer KH, Murray J, Parekh BS, Rice B, Robertson MN, Saito S, Vannappagari V, Warren M, Zeballos D, Zinserling J, Miller V. Promising results of HIV prevention trials highlight the benefits of collaboration in global health: The perspective of the Forum HIV Recency Assay Working Group. PLOS Glob Public Health. 2024; 4(10):e0003878.  View on PubMed
  16. Gulick RM, Pau AK, Daar E, Evans L, Gandhi RT, Tebas P, Ridzon R, Masur H, Lane HC, NIH COVID-19 Treatment Guidelines Panel, Adimora AA, Baker J, Kreuziger LB, Bedimo R, Belperio P, Bhalla A, Burgess T, Campbell D, Cantrill S, Chew K, Chiotos K, Coopersmith C, Davey R, Dzierba A, Eisnor D, Eschenauer G, Francis J, Gallagher J, Glidden D, Goldenberg N, Grund B, Han A, Hardy E, Harrison C, Henderson L, Higgs E, Hinkson C, Hughes B, Johnson S, Keller M, Kim A, Knight R, Kuriakose S, Lennox J, Lerner A, Levy M, Li J, MacBrayne C, Martin G, Nadig N, Nason M, Patel P, Pavia A, Proschan M, Schulert G, Seam N, Sheikh V, Simpson S, Singh K, Swindells S, Tien P, Uyeki T, Waghmare A, Wolfe C, Yazdany J, Aberg J. National Institutes of Health COVID-19 Treatment Guidelines Panel: Perspectives and Lessons Learned. Ann Intern Med. 2024 Nov; 177(11):1547-1557.  View on PubMed
  17. Spinelli MA, Johnson MO, Lisha NE, Jain JP, Moreira CV, Glidden DV, Burkholder GA, Crane HM, Jacobson JM, Cachay ER, Mayer KH, Napravnik S, Moore RD, Gandhi M, Christopoulos KA. Prevalence and Correlates of SARS-CoV-2 Vaccine Uptake and Hesitancy Among People With HIV Across the United States. J Acquir Immune Defic Syndr. 2024 Sep 01; 97(1):13-18.  View on PubMed
  18. Lu S, Peluso MJ, Glidden DV, Davidson MC, Lugtu K, Pineda-Ramirez J, Tassetto M, Garcia-Knight M, Zhang A, Goldberg SA, Chen JY, Fortes-Cobby M, Park S, Martinez A, So M, Donovan A, Viswanathan B, Hoh R, Donohue K, McIlwain DR, Gaudiliere B, Anglin K, Yee BC, Chenna A, Winslow JW, Petropoulos CJ, Deeks SG, Briggs-Hagen M, Andino R, Midgley CM, Martin JN, Saydah S, Kelly JD. Early biological markers of post-acute sequelae of SARS-CoV-2 infection. Nat Commun. 2024 Aug 29; 15(1):7466.  View on PubMed
  19. Byakwaga H, Semeere A, Laker-Oketta M, Busakhala N, Freeman E, Rotich E, Wenger M, Kadama-Makanga P, Kisuya J, Semakadde M, Mwine B, Kasozi C, Mwebesa B, Maurer T, Glidden DV, Wools-Kaloustian K, Kambugu A, Martin J. Survival Following Diagnosis of HIV-Associated Kaposi Sarcoma Among Adults in East Africa in the "Treat-All" Era. medRxiv. 2024 Aug 28.  View on PubMed
  20. Koss CA, Gandhi M, Halvas EK, Okochi H, Chu C, Glidden DV, Georgetti Gomez L, Heaps AL, Conroy AA, Tran M, Shetler C, Hoeth D, Kuncze K, Louie A, Rivera Garza H, Wafula Mugoma E, Penrose KJ, Chohan BH, Ayieko JO, Mills A, Patel RR, Mellors JW, Parikh UM. First Case of HIV Seroconversion With Integrase Resistance Mutations on Long-Acting Cabotegravir for Prevention in Routine Care. Open Forum Infect Dis. 2024 Sep; 11(9):ofae468.  View on PubMed

Go to UCSF Profiles, powered by CTSI